Background: National performance measures monitor the proportion of diabetic patients with low-density lipoprotein (LDL) levels >/=130 mg/dL, but such simple intermediate outcomes measure poor control, not necessarily poor care. "Tightly linked" quality measures define good quality either by a good intermediate outcome (LDL <130 mg/dL) or by evidence of appropriate responses to poor control (eg, starting or optimizing medications for high LDL or not doing so in the face of contraindications).
Objectives: We examined hyperlipidemia therapy for patients with diabetes to determine the relative accuracy of quality assessment using simple intermediate outcome versus tightly linked quality measures.
Research Design: Retrospective longitudinal cohort.
Subjects: A total of 1154 diabetic patients with an LDL test done between October 1, 1998, and March 31, 1999, in 2 large VA facilities.
Measures: LDL levels, medication treatment, and explanations for poor quality.
Results: Although 27% (307 of 1154) of patients had an LDL >/=130 mg/dL using the simple intermediate outcome measure, only 13% (148 of 1154) were classified as having substandard quality using the tightly linked measure. Among the 159 reclassified to adequate quality, 117 had lipid-lowering medication started or increased within 6 months of an LDL >/=130 mg/dL, 8 were already on high-dose medication, 12 had a repeat LDL <130 mg/dL, and 22 had contraindications to treatment.
Conclusion: Simple intermediate outcome measures can be an inaccurate reflection of true quality of care, and many patients classified as having substandard quality by "poor control" might actually be receiving good quality of care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.MLR.0000088453.57269.29 | DOI Listing |
Purpose: To evaluate the effect of osilodrostat and hypercortisolism control on blood pressure (BP) and glycemic control in patients with Cushing's disease.
Methods: Pooled analysis of two Phase III osilodrostat studies (LINC 3 and LINC 4), both comprising a 48-week core phase and an optional open-label extension. Changes from baseline in systolic and diastolic BP (SBP and DBP), fasting plasma glucose (FPG), and glycated hemoglobin (HbA) were evaluated during osilodrostat treatment in patients with/without hypertension or diabetes at baseline.
Cureus
December 2024
Diagnostic Radiology, Lady Reading Hospital Peshawar, Peshawar, PAK.
Introduction Rising prevalence rates of type 2 diabetes mellitus (T2DM), particularly in younger populations, have made early-onset T2DM (diagnosed before age 40) an increasingly significant health concern. Early-onset T2DM is often associated with more rapid progression and increased complications, including cardiovascular disease (CVD). However, its specific impact on cardiovascular outcomes remains inadequately understood, particularly compared to T2DM in older populations.
View Article and Find Full Text PDFJAMA Cardiol
January 2025
Cardiology Division, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Mymensingh Med J
January 2025
Dr Subir Ananda Biswas, Resident, Department of Paediatric Gastroenterology & Nutrition, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh; E-mail:
Cholestatic jaundice is a potentially serious condition that requires early diagnosis for proper management. Fat-soluble vitamin (FSV) deficiency develops as a consequence of cholestasis. Vitamin D deficiency is common and remains a challenge in patients with cholestasis.
View Article and Find Full Text PDFClin Exp Rheumatol
December 2024
Rheumatology Division, Central University Hospital of Asturias, Oviedo; Department of Medicine, Oviedo University School of Medicine, Oviedo; and Translational Immunology Division, Biohealth Research Institute of the Principality of Asturias (ISPA), Oviedo, Spain.
Objectives: Inflammatory biomarkers such as C-reactive protein (CRP) lack discriminatory capacity to detect active disease in psoriatic arthritis (PsA). Our aim was to find CRP thresholds capable of discriminating active disease in both early and established PsA.
Methods: We included a total of 345 PsA patients (215 early-onset not exposed to high-impact therapies and 130 with established disease under biologics and oral targeted therapies).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!